Impact of Bacille Calmette-Guérin revaccination on serum IgE levels in a randomized controlled trial

Peleteiro, Thaís Silva; Oliveira, Evelin Santos; Conceição, Elisabete Lopes; Nascimento-Sampaio, Francisco S.; Alcântara-Neves, Neuza Maria; Mendes, Carlos Maurício Cardeal; Barbosa, Theolis

doi:10.1590/0037-8682-0081-2017

Cited by 2 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the remaining 181 studies, 161 studies were excluded after reviewing the full text. In total, 20 articles including 222928 participants met the inclusion criteria and were included in the meta-analysis [11,[23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41]. e flow diagram of trial identification and selection is shown in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

BCG Vaccination in Early Childhood and Risk of Atopic Disease: A Systematic Review and Meta-Analysis

Zhao

Miles

Jiang

et al. 2021

Canadian Respiratory Journal

View full text Add to dashboard Cite

Background. Several large-scale studies suggest that Bacille Calmette–Guerin (BCG) vaccination in early childhood may reduce the risk of atopic diseases, but the findings remain controversial. Here, we aimed to investigate the potential correlation between early childhood BCG vaccination and the risk of developing atopic diseases. Methods. Eligible studies published on PubMed, EMBASE, and Cochrane CENTRAL were systematically sourced from 1950 to July 2021. Studies with over 100 participants and focusing on the association between BCG vaccine and atopic diseases including eczema, asthma, and rhinitis were included. Preliminary assessment of methods, interventions, outcomes, and study quality was performed by two independent investigators. Odds ratio (OR) with 95% confidence interval (CI) was calculated. Random effects of the meta-analysis were performed to define pooled estimates of the effects. Results. Twenty studies with a total of 222,928 participants were selected. The quantitative analysis revealed that administering BCG vaccine in early childhood reduced the risk of developing asthma significantly (OR 0.77, 95% CI 0.63 to 0.93), indicating a protective efficacy of 23% against asthma development among vaccinated children. However, early administration of BCG vaccine did not significantly reduce the risk of developing eczema (OR 0.94, 95% CI 0.76 to 1.16) and rhinitis (OR 0.99, 95% CI 0.81 to 1.21). Further analysis revealed that the effect of BCG vaccination on asthma prevalence was significant especially in developed countries (OR 0.73, 95% CI 0.58 to 0.92). Conclusion. BCG vaccination in early childhood is associated with reduced risk of atopic disease, especially in developed countries.

show abstract

Section: Resultsmentioning

confidence: 99%

BCG Vaccination in Early Childhood and Risk of Atopic Disease: A Systematic Review and Meta-Analysis

Zhao

Miles

Jiang

et al. 2021

Canadian Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…Five trials, [24,[26][27][28]30] were individually randomised, while one [29] was a cluster-randomised controlled trial. Ten of the 12 included articles were multiple publications [25,31,32,33,34,35] based on four included studies. [24,26,27,29] This is shown in the PRISMA flow diagram (Figure 1).…”

Section: Resultsmentioning

confidence: 99%

Booster Dose of Bacille Calmette-Guérin Vaccine for Tuberculosis in Low and Middle-Income Countries: A Systematic Review

Oduwole¹,

Mwankon²,

Okebe³

et al. 2021

Ann Health Res

View full text Add to dashboard Cite

Background: The Bacille Calmette-Guérin (BCG) vaccine, given as a single dose, offers variable protection against Tuberculosis (TB). It is plausible that repeat doses could improve the effectiveness of the BCG vaccine in settings where the population remain at risk of the disease. Objective: To assess the effectiveness of BCG revaccination as a booster dose in preventing TB in Low- and Middle- Income Countries (LMICs). Methods: We searched the electronic databases without language or publication restrictions and followed the procedures for preparing systematic reviews, including assessing the risk of bias as outlined in the Cochrane handbook. We included randomised controlled trials (RCTs) conducted in LMICs involving children and adults receiving one or more BCG vaccine doses after the primary BCG vaccination. The incidence of severe forms of TB, active TB and adverse events were the primary outcomes. Results: Five RCTs were included in this systematic review. Revaccination with BCG probably makes little or no difference to the risk of active TB measured after five years (Relative risk (RR) 1.16, 95% CI 0.88 to 1.51; 348,083 participants; one study, moderate certainty evidence) or nine years post-revaccination (RR 0.96, 95% CI 0.82 to 1.12; 348,083 participants; one study, moderate certainty evidence). In populations with HIV co-infection, revaccination probably increases the risk of pulmonary tuberculosis compared to placebo (RR 1.74, 95% CI 1.00 to 3.01; 46,764 participants; one study, moderate certainty evidence). Conclusion: The available evidence suggests that BCG revaccination probably makes little or no difference in preventing tuberculosis disease in LMICs.

show abstract

Impact of Bacille Calmette-Guérin revaccination on serum IgE levels in a randomized controlled trial

Abstract: BCG responsiveness does not affect protection against atopy.

Cited by 2 publications

References 17 publications

BCG Vaccination in Early Childhood and Risk of Atopic Disease: A Systematic Review and Meta-Analysis

BCG Vaccination in Early Childhood and Risk of Atopic Disease: A Systematic Review and Meta-Analysis

Booster Dose of Bacille Calmette-Guérin Vaccine for Tuberculosis in Low and Middle-Income Countries: A Systematic Review

Contact Info

Product

Resources

About